JNJ
Johnson & Johnson$227.08+1.67 (+0.74%)Prev Close$225.34·MCap$555.94B·P/E25.98·Vol3.03M·Yield0.02%
▲
Buys (12M)
1
$257.7K
▼
Sells (12M)
24
$172.30M
◆
Net Activity
Net Seller
$172.04M
●
Active Insiders
13
last 12 mo
Over the past 12 months, insider activity at Johnson & Johnson (JNJ) has been dominated by selling, with 1 insider purchase totaling $257.7K and 24 insider sales totaling $172.30M. The most recent insider transaction was by Decker Robert J (officer: VP Corporate Controller), who sold $1.01M worth of shares on Mar 3, 2026. Johnson & Johnson operates in the Healthcare sector, within the Drug Manufacturers - General industry, with a market cap of $555.94B.
JNJ Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | Decker Robert J | officer: VP Corporate Controller | Sell | 4,075 | $247.87 | $1.01M | 23,682 |
| Feb 20, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 1,322 | $245.66 | $324.8K | 0 |
| Feb 18, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 7,266 | $244.45 | $1.78M | 0 |
| Feb 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 54,844 | $243.01 | $13.33M | 0 |
| Feb 13, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | Sell | 10,611 | $243.82 | $2.59M | 0 |
| Feb 13, 2026 | Decker Robert J | VP Corporate Controller | Sell | 1,055 | $244.35 | $257.8K | 0 |
| Feb 13, 2026 | Duato Joaquin | CEO and Chairman of the Board | Sell | 36,230 | $244.44 | $8.86M | 0 |
| Feb 13, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | Sell | 8,361 | $244.41 | $2.04M | 0 |
| Feb 13, 2026 | Mulholland Kristen | EVP, Chief HR Officer | Sell | 1,585 | $244.26 | $387.1K | 0 |
| Feb 13, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 24,910 | $244.33 | $6.09M | 0 |
| Feb 13, 2026 | Swanson James D. | EVP, CIO | Sell | 66,293 | $243.46 | $16.14M | 0 |
| Feb 13, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 15,717 | $244.43 | $3.84M | 0 |
| Feb 13, 2026 | Wolk Joseph J | Exec VP, CFO | Sell | 107,784 | $243.08 | $26.20M | 0 |
| Jan 28, 2026 | Duato Joaquin | director, officer: CEO and Chairman of the Board | Sell | 200,000 | $221.23 | $44.25M | 79,634-72% |
| Dec 1, 2025 | JOHNSON & JOHNSON | 10% Owner | Sell | 6,337 | $10.03 | $63.6K | 0 |
| Dec 1, 2025 | MORIKIS JOHN G | Director | Buy | 1,250 | $206.15 | $257.7K | 0 |
| Nov 25, 2025 | JOHNSON & JOHNSON | 10% Owner | Sell | 2,700 | $10.05 | $27.1K | 0 |
| Nov 14, 2025 | JOHNSON & JOHNSON | 10% Owner | Sell | 1,000 | $10.00 | $10.0K | 0 |
| Nov 10, 2025 | JOHNSON & JOHNSON | 10% Owner | Sell | 52,532 | $10.21 | $536.3K | 0 |
| Oct 20, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 21,721 | $192.71 | $4.19M | 0 |
| Sep 5, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 56,471 | $177.81 | $10.04M | 0 |
| Sep 3, 2025 | Forminard Elizabeth | Executive VP, General Counsel | Sell | 9,570 | $177.20 | $1.70M | 0 |
| Aug 25, 2025 | Duato Joaquin | CEO and Chairman of the Board | Sell | 125,824 | $179.21 | $22.55M | 0 |
| Aug 18, 2025 | Wolk Joseph J | Exec VP, CFO | Sell | 16,820 | $176.91 | $2.98M | 0 |
| Jul 18, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 19,137 | $163.55 | $3.13M | 0 |
| Feb 26, 2025 | Decker Robert J | VP Corporate Controller | Sell | 6,999 | $165.88 | $1.16M | 0 |
| Feb 18, 2025 | Decker Robert J | VP Corporate Controller | Sell | 824 | $156.46 | $128.9K | 0 |
| Feb 18, 2025 | Forminard Elizabeth | Executive VP, General Counsel | Sell | 1,253 | $156.32 | $195.9K | 0 |
| Feb 18, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 385 | $156.15 | $60.1K | 0 |
| Feb 18, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 2,250 | $156.49 | $352.1K | 0 |
| Feb 18, 2025 | Swanson James D. | EVP, CIO | Sell | 1,740 | $156.54 | $272.4K | 0 |
| Feb 18, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 3,296 | $156.58 | $516.1K | 0 |
| Feb 18, 2025 | Wolk Joseph J | Exec VP, CFO | Sell | 9,080 | $156.58 | $1.42M | 0 |
| Feb 11, 2025 | Duato Joaquin | CEO and Chairman of the Board | Sell | 100,643 | $153.12 | $15.41M | 0 |
| Feb 11, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 47,436 | $153.12 | $7.26M | 0 |
| Feb 11, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 26,076 | $153.12 | $3.99M | 0 |
| Jul 27, 2023 | Fasolo Peter | Exec VP, Chief HR Officer | Sell | 20,000 | $170.32 | $3.41M | 102,696 |
| Jul 27, 2023 | Hait William | See Remarks | Sell | 14,698 | $172.00 | $2.53M | 87,747 |
| Jun 14, 2023 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 12,465 | $160.00 | $1.99M | 65,934 |
| Mar 8, 2023 | Swanson James D. | See Remarks | Sell | 1,061 | $154.66 | $164.1K | 9,215 |
| Dec 15, 2022 | Wolk Joseph J | Exec VP, CFO | Sell | 14,781 | $179.60 | $2.65M | 48,738 |
| Dec 2, 2022 | McEvoy Ashley | EVP, WW Chair, MedTech | Sell | 73,323 | $175.47 | $12.87M | 113,736-39% |
| Nov 23, 2022 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | Sell | 76,923 | $176.78 | $13.60M | 126,456-38% |
| Nov 21, 2022 | Decker Robert J | Controller, CAO | Sell | 16,928 | $175.00 | $2.96M | 15,473-52% |
| Nov 10, 2022 | Wengel Kathryn E | EVP, Chief GSC Officer | Sell | 16,410 | $173.42 | $2.85M | 71,311 |
| Nov 8, 2022 | Mongon Thibaut | Exec VP, WW Chair, Consumer | Sell | 35,246 | $171.18 | $6.03M | 58,426-38% |
| Oct 26, 2022 | Fasolo Peter | Exec VP, Chief HR Officer | Sell | 24,675 | $171.36 | $4.23M | 143,121 |
| Dec 9, 2021 | Decker Robert J | Controller, CAO | Sell | 5,000 | $163.21 | $816.0K | 14,215-26% |
JNJ Insider Buying Activity
The following table shows recent insider purchases of Johnson & Johnson (JNJ) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Dec 1, 2025 | MORIKIS JOHN G | Director | Buy | 1,250 | $206.15 | $257.7K | 0 |
JNJ Insider Selling Activity
The following table shows recent insider sales of Johnson & Johnson (JNJ) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | Decker Robert J | officer: VP Corporate Controller | Sell | 4,075 | $247.87 | $1.01M | 23,682 |
| Feb 20, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 1,322 | $245.66 | $324.8K | 0 |
| Feb 18, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 7,266 | $244.45 | $1.78M | 0 |
| Feb 15, 2026 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 54,844 | $243.01 | $13.33M | 0 |
| Feb 13, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | Sell | 10,611 | $243.82 | $2.59M | 0 |
| Feb 13, 2026 | Decker Robert J | VP Corporate Controller | Sell | 1,055 | $244.35 | $257.8K | 0 |
| Feb 13, 2026 | Duato Joaquin | CEO and Chairman of the Board | Sell | 36,230 | $244.44 | $8.86M | 0 |
| Feb 13, 2026 | Forminard Elizabeth | EVP, Chief Legal Officer | Sell | 8,361 | $244.41 | $2.04M | 0 |
| Feb 13, 2026 | Mulholland Kristen | EVP, Chief HR Officer | Sell | 1,585 | $244.26 | $387.1K | 0 |
| Feb 13, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 24,910 | $244.33 | $6.09M | 0 |
| Feb 13, 2026 | Swanson James D. | EVP, CIO | Sell | 66,293 | $243.46 | $16.14M | 0 |
| Feb 13, 2026 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 15,717 | $244.43 | $3.84M | 0 |
| Feb 13, 2026 | Wolk Joseph J | Exec VP, CFO | Sell | 107,784 | $243.08 | $26.20M | 0 |
| Jan 28, 2026 | Duato Joaquin | director, officer: CEO and Chairman of the Board | Sell | 200,000 | $221.23 | $44.25M | 79,634-72% |
| Dec 1, 2025 | JOHNSON & JOHNSON | 10% Owner | Sell | 6,337 | $10.03 | $63.6K | 0 |
| Nov 25, 2025 | JOHNSON & JOHNSON | 10% Owner | Sell | 2,700 | $10.05 | $27.1K | 0 |
| Nov 14, 2025 | JOHNSON & JOHNSON | 10% Owner | Sell | 1,000 | $10.00 | $10.0K | 0 |
| Nov 10, 2025 | JOHNSON & JOHNSON | 10% Owner | Sell | 52,532 | $10.21 | $536.3K | 0 |
| Oct 20, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 21,721 | $192.71 | $4.19M | 0 |
| Sep 5, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 56,471 | $177.81 | $10.04M | 0 |
| Sep 3, 2025 | Forminard Elizabeth | Executive VP, General Counsel | Sell | 9,570 | $177.20 | $1.70M | 0 |
| Aug 25, 2025 | Duato Joaquin | CEO and Chairman of the Board | Sell | 125,824 | $179.21 | $22.55M | 0 |
| Aug 18, 2025 | Wolk Joseph J | Exec VP, CFO | Sell | 16,820 | $176.91 | $2.98M | 0 |
| Jul 18, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 19,137 | $163.55 | $3.13M | 0 |
| Feb 26, 2025 | Decker Robert J | VP Corporate Controller | Sell | 6,999 | $165.88 | $1.16M | 0 |
| Feb 18, 2025 | Decker Robert J | VP Corporate Controller | Sell | 824 | $156.46 | $128.9K | 0 |
| Feb 18, 2025 | Forminard Elizabeth | Executive VP, General Counsel | Sell | 1,253 | $156.32 | $195.9K | 0 |
| Feb 18, 2025 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 385 | $156.15 | $60.1K | 0 |
| Feb 18, 2025 | Schmid Timothy | EVP, WW Chair, MedTech | Sell | 2,250 | $156.49 | $352.1K | 0 |
| Feb 18, 2025 | Swanson James D. | EVP, CIO | Sell | 1,740 | $156.54 | $272.4K | 0 |
| Feb 18, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 3,296 | $156.58 | $516.1K | 0 |
| Feb 18, 2025 | Wolk Joseph J | Exec VP, CFO | Sell | 9,080 | $156.58 | $1.42M | 0 |
| Feb 11, 2025 | Duato Joaquin | CEO and Chairman of the Board | Sell | 100,643 | $153.12 | $15.41M | 0 |
| Feb 11, 2025 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sell | 47,436 | $153.12 | $7.26M | 0 |
| Feb 11, 2025 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 26,076 | $153.12 | $3.99M | 0 |
| Jul 27, 2023 | Fasolo Peter | Exec VP, Chief HR Officer | Sell | 20,000 | $170.32 | $3.41M | 102,696 |
| Jul 27, 2023 | Hait William | See Remarks | Sell | 14,698 | $172.00 | $2.53M | 87,747 |
| Jun 14, 2023 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 12,465 | $160.00 | $1.99M | 65,934 |
| Mar 8, 2023 | Swanson James D. | See Remarks | Sell | 1,061 | $154.66 | $164.1K | 9,215 |
| Dec 15, 2022 | Wolk Joseph J | Exec VP, CFO | Sell | 14,781 | $179.60 | $2.65M | 48,738 |
| Dec 2, 2022 | McEvoy Ashley | EVP, WW Chair, MedTech | Sell | 73,323 | $175.47 | $12.87M | 113,736-39% |
| Nov 23, 2022 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | Sell | 76,923 | $176.78 | $13.60M | 126,456-38% |
| Nov 21, 2022 | Decker Robert J | Controller, CAO | Sell | 16,928 | $175.00 | $2.96M | 15,473-52% |
| Nov 10, 2022 | Wengel Kathryn E | EVP, Chief GSC Officer | Sell | 16,410 | $173.42 | $2.85M | 71,311 |
| Nov 8, 2022 | Mongon Thibaut | Exec VP, WW Chair, Consumer | Sell | 35,246 | $171.18 | $6.03M | 58,426-38% |
| Oct 26, 2022 | Fasolo Peter | Exec VP, Chief HR Officer | Sell | 24,675 | $171.36 | $4.23M | 143,121 |
| Dec 9, 2021 | Decker Robert J | Controller, CAO | Sell | 5,000 | $163.21 | $816.0K | 14,215-26% |
JNJ Insiders
Similar Stocks to JNJ
LLY
Eli Lilly and Company
$864.41-0.44%
$869.14B
ABBV
AbbVie Inc.
$196.56-0.44%
$360.31B
MRK
Merck & Co., Inc.
$110.50+0.25%
$289.58B
AMGN
Amgen Inc.
$340.40+0.04%
$188.76B
GILD
Gilead Sciences, Inc.
$128.66+0.73%
$168.65B
PFE
Pfizer Inc.
$26.61-0.65%
$156.54B
BMY
Bristol-Myers Squibb Company
$57.98+0.37%
$120.73B
BIIB
Biogen Inc.
$183.00+1.28%
$26.91B